Cord blood therapy offered for long COVID sufferers
NCT ID NCT07332338
First seen Jan 12, 2026 · Last updated Jun 22, 2026 · Updated 26 times
Summary
This expanded access program offers an infusion of umbilical cord blood cells (REGENECYTE) to adults with long COVID who are not eligible for other trials. The goal is to see if it can ease persistent symptoms like fatigue. Participants must have a recent negative COVID-19 test and provide consent.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
D&H National Research Center #1
AVAILABLEMiami, Florida, 33169, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Myrak Research Center Inc.
AVAILABLEMiami Lakes, Florida, 33014, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
umbilical cord blood cells (REGENECYTE)
What this could lead to
If it works, this could point toward a treatment that reduces long COVID symptoms like chronic fatigue.
What could go wrong
This is an expanded access program, not a formal trial, so evidence is limited. It may not help everyone and risks include infusion reactions or infection.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.